Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vaxzevria (COVID-19 vaccine, ChAdOx1-S [recombinant]) is indicated for the active immunization of individuals 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).
• Fourteen studies were analyzed to gather information about Vaxzevria.
• Vaxzevria has been found effective and safe in the Autoimmune Rheumatic Diseases (ARD) population. However, responses could be suboptimal in individuals on certain immunomodulatory medications or with specific comorbidities.
• In African populations, Vaxzevria demonstrated wide-ranging efficacy against COVID-19 and its variants, with adverse events generally being mild to moderate, supporting the safety profile of this vaccine.
• Vaccine effectiveness, including that of Vaxzevria for preventing infections, hospitalizations, and mortality, tends to decrease over time. As a result, booster doses are recommended.
• Rare instances have linked Vaxzevria with Transverse Myelitis (TM), especially among higher age groups, where recovery was poorer compared to others.
• Vaxzevria has also been associated with Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), a condition that presents challenges in diagnosis but remains rare relative to the number of doses administered.
• Thromboembolic events post-vaccination have occurred after administering this vaccine; some cases resulted in fatality, emphasizing the need for awareness and prompt management.